Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?
Halozyme Therapeutics (HALO) recently elected Dannielle Appelhans to its Board of Directors, following strong share price returns, increased revenue, and ongoing buybacks. While analysts generally view HALO as 20.7% overvalued with a fair value of $86.89, a Discounted Cash Flow (DCF) model by Simply Wall St suggests a much higher fair value of $405.09. Investors are encouraged to review both perspectives to make informed decisions.
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO
Aurora Investment Counsel has acquired a new stake of 18,233 shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO), valued at approximately $1.43 million, during the second quarter. This move is part of broader institutional investor activity, with several other firms also adjusting their holdings in the biopharmaceutical company. Meanwhile, company insiders, including Director Bernadette Connaughton and CEO Helen Torley, have recently sold shares, though institutional investors collectively own a significant 97.79% of the stock.
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock
Halozyme Therapeutics CEO Helen Torley sold 20,000 shares of the company's stock for over $2 million, executed under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her holdings by 2.54%. The company recently exceeded analyst estimates with strong quarterly earnings and revenue growth, leading to a "Moderate Buy" consensus rating from analysts.
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares
Halozyme (NASDAQ: HALO) President and CEO Helen Torley exercised stock options and sold 60,000 common shares between August 17-19, 2026, under a pre-arranged Rule 10b5-1 trading plan. She exercised options at $18.41 per share and sold the shares in the high $90s to approximately $108 per share. These options were part of a grant from February 2018, set to expire in February 2028.
Halozyme Appoints Dannielle Appelhans to Board of Directors
Halozyme Therapeutics has appointed Dannielle Appelhans to its Board of Directors, effective August 14, 2026. She joins as a non-employee director with standard compensation and no initial committee assignments. Analysts currently rate HALO as a "Buy" with a $115.00 price target, and TipRanks' AI Analyst, Spark, also rates it as Outperform due to strong financial performance and positive earnings updates.
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?
Halozyme Therapeutics (HALO) recently appointed Dannielle Appelhans to its Board of Directors, following strong share price momentum and positive financial signals. While analysts' consensus fair value suggests the stock is 20.7% overvalued at $86.89, Simply Wall St's DCF model indicates a significantly higher fair value of $405.09. The article highlights both the optimistic outlook based on earnings guidance and buybacks, and concerns about concentration risk and patent challenges.
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO
Diversify Advisory Services LLC has acquired a new stake of 33,976 shares, valued at approximately $2.77 million, in Halozyme Therapeutics, Inc. This makes them one of many institutional investors, who collectively own 97.79% of the company. Halozyme Therapeutics recently reported strong quarterly earnings, beating analyst estimates, and has received a consensus "Moderate Buy" rating from analysts with an average price target of $91.20.
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO
Foster & Motley Inc. has acquired a new stake of $2 million in Halozyme Therapeutics (NASDAQ:HALO) during the second quarter, bringing institutional ownership to 97.79%. Halozyme Therapeutics reported strong quarterly results, surpassing EPS and revenue estimates, and provided positive fiscal 2026 EPS guidance, although insiders sold shares worth $3.14 million. Analyst sentiment for the biopharmaceutical company is generally positive, with a "Moderate Buy" consensus.
Halozyme Appoints Dannielle Appelhans to its Board of Directors
Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings over 20 years of executive leadership in the biotechnology and pharmaceutical industries, with significant expertise in operations, manufacturing, and supply chain management. Her experience will be a key asset as Halozyme continues to advance its drug delivery technology platforms and growth strategy.
Halozyme adds Dannielle Appelhans to board of directors
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of Dannielle Appelhans to its board of directors. Appelhans, currently CEO of COUR Pharmaceuticals, brings extensive experience from her previous roles at Rubius Therapeutics, Inc., Novartis, McKinsey & Company, and Eli Lilly and Company. Her operational and manufacturing expertise is expected to support Halozyme's growth strategy.
Halozyme Therapeutics stock hits all-time high of 104.86 USD
Halozyme Therapeutics Inc. (HALO) stock reached an all-time high of $104.86, driven by strong investor confidence and positive market sentiment. The company reported impressive Q2 2026 financial results, surpassing Wall Street expectations with higher-than-estimated non-GAAP earnings and revenue, leading to an increased full-year outlook. Analysts at Citizens and H.C. Wainwright reiterated positive ratings and price targets, citing significant royalty revenue growth and positive clinical trial data.
Does Halozyme’s Raised 2026 Revenue Outlook And Aggressive Buybacks Change The Bull Case For HALO?
Halozyme Therapeutics reported strong Q2 2026 results with increased revenue and net income, alongside significant share repurchases of 13.45 million shares for $750 million. The company also raised its 2026 revenue guidance to between $1.84 billion and $1.91 billion, signaling management's confidence. This performance reinforces the investment narrative around ENHANZE-driven royalty growth, although investors still need to consider ongoing patent challenges and the concentration risk associated with key partners.
Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals
Halozyme Therapeutics insider Helen Torley has filed a Form 144, indicating a proposed sale of 240,000 shares of common stock with an aggregate market value of $23,678,400. This follows previous sales by Torley totaling 51,923 shares over the past three months, generating over $3.5 million. The filing also notes that Halozyme has 113,498,000 shares of common stock outstanding.
Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO
Horizon Investment Services LLC has acquired 28,793 shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) worth approximately $2.25 million in the second quarter. This move is part of broader institutional investment, with collective ownership by institutional investors and hedge funds standing at 97.79%. Halozyme Therapeutics recently reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating from analysts.
Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO
Chase Investment Counsel Corp has acquired a new stake of 26,000 shares in Halozyme Therapeutics, valued at approximately $2.0 million. This comes as institutional investors now collectively own 97.79% of the company. Despite insider selling activity, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $91.20, with some analysts raising their targets even higher.
Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO
Wedge Capital Management L L P NC has invested $31.61 million in Halozyme Therapeutics, Inc., acquiring 403,824 shares. Halozyme Therapeutics, a biopharmaceutical company, reported strong quarterly results with EPS of $2.28 and revenue of $481 million, exceeding analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts, despite recent insider share sales by its CEO and a director.
Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO
Handelsbanken Fonder AB significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.1% in Q2 2026, now holding 631,899 shares valued at $49.5 million. This move is part of broader institutional investment, with various firms adjusting their holdings, and insiders also making transactions. Halozyme reported strong quarterly earnings and revenue, exceeding analyst expectations, and has received positive analyst ratings with a "Moderate Buy" consensus.
Halozyme director Connaughton sells $167,152 in shares
Halozyme Therapeutics director Bernadette Connaughton sold 1,626 shares of company stock for a total of $167,152 on August 10, 2026, at a price of $102.8 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025. Following the transaction, Connaughton directly holds 40,418 shares, as the stock trades near its 52-week high and is considered undervalued by InvestingPro.
Halozyme Therapeutics (HALO) director sells 1,626 shares in Rule 10b5-1 plan trade
Halozyme Therapeutics (HALO) director Bernadette Connaughton sold 1,626 shares of common stock at $102.80 per share on August 10, 2026, under a Rule 10b5-1 trading plan adopted in May 2025. Following this transaction, she directly holds 40,418 shares. The sale, valued at approximately $167,000, was reported via a Form 4 SEC filing.
Halozyme Therapeutics (HALO) affiliate plans stock option-related share sales in Form 144
Halozyme Therapeutics (HALO) filed a Form 144, indicating an affiliate's intention to sell common stock through Morgan Stanley Smith Barney LLC. These planned sales are linked to stock option exercises set for August 11, 2026, involving transactions for 32,659, 5,277, and 3,766 shares of common stock. The filing aims to ensure transparency regarding these upcoming share disposals.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Analysts
Halozyme Therapeutics (NASDAQ:HALO) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $91.20, though some targets have been raised to $115. The company exceeded quarterly expectations with $2.28 EPS and $481 million in revenue, leading to positive fiscal 2026 EPS guidance. While institutional investors largely hold the stock, insiders have recently sold shares worth approximately $3.67 million.
What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation
Halozyme Therapeutics (HALO) recently reported strong Q2 earnings, with revenue of US$481 million and net income of US$229.91 million, leading to raised full-year revenue guidance and new collaboration agreements. Despite a significant 1-year share price return of 63.17%, the company faces mixed valuation signals, with one narrative suggesting it's 18.1% overvalued at $102.62, while a discounted cash flow model indicates it is undervalued with a fair value of US$403.52. Investors are encouraged to review both the potential upsides, driven by expanding partnerships and subcutaneous biologic launches, and key risks such as revenue concentration and patent challenges.
Halozyme Therapeutics (HALO) insider schedules 1,626-share stock sale via trading plan
Halozyme Therapeutics insider Bernadette Connaughton plans to sell 1,626 shares of common stock, valued at $167,673.12, through Morgan Stanley Smith Barney LLC on August 10, 2026. These shares originated from Restricted Stock Units granted in April 2025. The filing also details prior sales under a Rule 10b5-1 trading plan, including 1,625 shares sold in July 2026 and another 1,625 shares sold in June 2026.
Gradient Investments LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO
Gradient Investments LLC has purchased a new stake in Halozyme Therapeutics, Inc. ($HALO), acquiring 16,437 shares valued at approximately $1.29 million. This investment comes as Halozyme reported a strong second quarter with significant revenue growth and raised its 2026 guidance, attracting positive analyst sentiment. Despite some insider selling, institutional ownership remains high at 97.79%, and the company continues to expand its commercial pipeline.
Earnings Update: Halozyme Therapeutics, Inc. Beat Earnings And Now Analysts Have New Forecasts For This Year
Halozyme Therapeutics, Inc. reported a strong quarter, exceeding analysts' earnings expectations. Following these results, analysts have updated their financial forecasts for the current year, indicating a positive outlook for the company's performance. This update reflects increased confidence in Halozyme's financial trajectory.
Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE Deals - Has The Bull Case Changed?
Halozyme Therapeutics reported record second-quarter results with revenue up to US$481 million and net income of US$229.91 million, leading to increased full-year 2026 revenue guidance. The company also accelerated share buybacks and secured new ENHANZE collaborations, reinforcing its royalty-led business model. While these achievements support the near-term investment narrative, key risks such as partner concentration, reimbursement pressures, and intellectual property challenges persist.
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks
Halozyme Therapeutics reported strong second-quarter results, with revenue rising to US$481 million and net income to US$229.91 million. The company also increased its full-year 2026 revenue guidance to a range of US$1.84 billion to US$1.91 billion and accelerated share repurchases, completing US$750 million under a 2024 authorization and an additional US$175.01 million under a new 2026 program. These actions, combined with five new ENHANZE collaboration deals, reinforce the company's investment narrative centered on its royalty model, despite ongoing legal and patent challenges.
Halozyme Therapeutics (HALO) Stock Looks Expensive At Today’s Price
Halozyme Therapeutics (HALO) has seen a 106.2% return over five years, but its current valuation suggests the stock is expensive, trading at 29.2x earnings compared to a fair P/E of 20.1x. Despite strong financial results and collaboration agreements, the company's P/E ratio is above the biotech industry average. The analysis concludes that the stock appears overvalued based on current fundamentals and that future returns depend on the company justifying its premium with strong margins and earnings.
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks
Halozyme Therapeutics reported record second-quarter results with revenue at US$481 million and net income at US$229.91 million, leading to a 24.9% stock increase. The company raised its 2026 revenue guidance to US$1.84 billion - US$1.91 billion and boosted share buybacks by an additional US$175.01 million under a new 2026 program, after completing US$750 million from 2024. This positive outlook is driven by its ENHANZE royalty engine, though legal and patent challenges remain a key risk for investors.
Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Raised to $99.56, Implies 16% Upside
Analysts have raised the average 12-month price target for Halozyme Therapeutics, Inc. (HALO) stock to $99.56, up from $86.89. This new target suggests a potential upside of approximately 16% from its recent closing price. The consensus rating among 11 analysts remains a "Buy," with 9 analysts recommending a Buy and 2 recommending a Hold.
Halozyme (HALO) Stock Rallies As Royalties Surge And Guidance Climbs
Halozyme Therapeutics (HALO) stock rallied 20% after reporting strong Q2 2026 earnings, exceeding revenue and EPS expectations, driven by a 47.5% increase in total revenue and 39.2% increase in net income. The company also raised its full-year 2026 revenue and earnings guidance, reinforcing its "compounding platform" bull case despite ongoing bear concerns about concentration and long-term patent durability.
Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO
Assenagon Asset Management S.A. significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4,578.9% in the second quarter, now holding 997,643 shares valued at $78.1 million. This increase follows Halozyme's strong second-quarter results, which exceeded analyst expectations with adjusted EPS of $2.28 and revenue of $481 million, leading to a raised 2026 guidance. Despite positive analyst sentiment and several price target increases, some valuation concerns persist as the stock trades above the consensus price target.
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen
Halozyme Therapeutics (NASDAQ:HALO) was upgraded to a "strong-buy" rating by Wall Street Zen following impressive quarterly results where EPS and revenue significantly beat estimates. The company also raised its 2026 guidance, driven by strong royalty growth and new ENHANZE and Hypercon agreements. Despite some mixed analyst views on its elevated valuation, several firms have increased their price targets for the stock.
Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike
Halozyme Therapeutics (HALO) surged by 19.44% after reporting Q2 earnings that significantly beat expectations, with non-GAAP EPS at $2.28 and revenue at $481M. The company also raised its 2026 non-GAAP EPS and revenue guidance above Street estimates, driven by strong royalty growth and new ENHANZE and Hypercon platform partnerships. This performance highlights Halozyme's strong economic model and positions it as a high-growth leader in the biotech industry.
Halozyme Therapeutics (HALO) Stock Looks Expensive At Today’s Price
Halozyme Therapeutics (HALO) has seen a significant 106.2% return over five years, but its current valuation suggests it may be expensive. The company's P/E ratio of 29.2x is above the biotech industry average, indicating overvaluation based on its growth, margins, size, and risk profile. Despite strong financial results and new collaborations, the stock's premium multiple raises questions about its future upside based on current fundamentals.
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to "Outperform" at Leerink Partners
Leerink Partners has upgraded Halozyme Therapeutics (NASDAQ:HALO) from "market perform" to "outperform," setting a $110 price target. This upgrade follows Halozyme's strong quarterly results, with revenue up 47.7% year-over-year and EPS significantly beating estimates, leading management to raise its fiscal 2026 outlook. The company also saw a 50% increase in royalty revenue and signed five new collaboration agreements, contributing to a "Moderate Buy" consensus rating from analysts.
HALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83
Leerink Partners has upgraded Halozyme Therapeutics, Inc. (HALO.O) from Market Perform to Outperform. The firm also increased its target price for Halozyme Therapeutics to $110, up from the previous $83. This suggests a more positive outlook on the company's stock performance.
Halozyme Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-08-07
Halozyme Therapeutics, Inc. (HALO) has published its Q2 2026 earnings call presentation, reporting significant financial beats. The company's EPS of $2.28 surpassed estimates by $0.46, and revenue reached $481.00M, exceeding expectations by $78.72M and showing a 47.67% year-over-year increase. This presentation was released in conjunction with their earnings call on August 7, 2026.
HALOZYME THERAPEUTICS, INC. 2026: Revenue $481M, EPS $1.9— 10-Q Summary
HALOZYME THERAPEUTICS, INC. reported strong financial results for the 2026 quarter, with revenue reaching $481 million and diluted EPS of $1.9. This growth was primarily driven by increased royalties, particularly from products like DARZALEX SC and VYVGART Hytrulo, and significant growth in bulk rHuPH20 sales. The company also expanded its operational capabilities through strategic acquisitions and partner deals, further boosting ENHANZE adoption.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) reported Q2 earnings of $2.28 per share and revenues of $481 million, both exceeding Zacks Consensus Estimates. The company has consistently surpassed revenue estimates and its shares have outperformed the S&P 500 this year, though its Zacks Rank is currently "Hold" indicating market-line performance expectations. Investors are now looking at future earnings outlook and industry trends to gauge the stock's next move.
Halozyme Therapeutics (NASDAQ: HALO) posts $481M Q2 2026 revenue
Halozyme Therapeutics (NASDAQ: HALO) reported total revenues of $481 million for Q2 2026 and $857.7 million for the first half of 2026, alongside a quarterly net income of $230 million. The biopharmaceutical company, which specializes in drug-delivery technologies like ENHANZE and Hypercon, saw significant growth in royalties and product sales. Halozyme also announced a new $1 billion share repurchase program valid until December 31, 2028, and detailed several new and expanded collaborations for its drug delivery platforms.
Earnings Flash (HALO) Halozyme Therapeutics, Inc. Reports Q2 Revenue $481.0M, vs. FactSet Est of $402.3M
Halozyme Therapeutics, Inc. (HALO) reported robust Q2 revenue of $481.0 million, significantly exceeding FactSet's estimate of $402.3 million. The biopharmaceutical company also updated its 2026 adjusted EPS guidance to a range of $8.65-$9.00, surpassing the FactSet estimate of $7.94, and raised its 2026 revenue expectations to $1.835B-$1.910B against an estimate of $1.77B. These strong financial results and updated forecasts suggest a positive outlook for the company.
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics, Inc. reported record second-quarter 2026 financial results, exceeding estimates and subsequently raising its full-year 2026 financial guidance. The company saw a 48% year-over-year increase in total revenue to $481 million, with royalty revenue growing 50% to $308 million, driven by the strong performance of its ENHANZE® partner products. Halozyme also expanded its collaboration agreements by signing five new ENHANZE® and Hypercon™ deals year-to-date and repurchased $333 million in shares.
Halozyme earnings up next: Can royalty growth hit $1B target?
Halozyme Therapeutics Inc. is reporting second-quarter earnings, with investors keenly watching its partnership momentum and progress toward a $1 billion ENHANZE royalty revenue target. The company has shown strong growth and secured multiple licensing deals, contributing to its stock trading near 52-week highs. Investors will focus on new partnership additions and the sustainability of its growth trajectory.
Halozyme Therapeutics, Inc. Revenue Breakdown – LSX:A0DLHS
Halozyme Therapeutics, Inc. generated 1.19 billion EUR in revenue last year, primarily from its Proprietary Enzymes, Devices, Hypercon Technology, and Surf Bio Technology segment. This revenue marks an increase from 980.78 million EUR in the previous year. The United States was the largest contributor, accounting for 700.70 million EUR of the company's revenue.
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
Halozyme Therapeutics (NASDAQ:HALO) is set to announce its Q2 earnings this Thursday. The company exceeded revenue expectations last quarter and analysts anticipate 24.1% year-on-year revenue growth for the upcoming report. Peers Biogen and Amgen have already reported strong Q2 results, with the therapeutics segment generally seeing share price increases.
4% Undervalued? Halozyme Therapeutics (HALO) Nears Earnings At A Record High
Halozyme Therapeutics (HALO) has reached a record high ahead of its earnings release, driven by a 30.82% share price return over 90 days and a 94.35% return over three years. While analysts view it as slightly undervalued with a fair value of $86.89, its P/E ratio of 28.3x is higher than the industry average, suggesting potential risks despite promising royalty streams from its drug delivery platform. Investors are encouraged to review the full data and consider both rewards and risks.
Halozyme Therapeutics Inc (HALO) - Tradingkey Stock Score & Comprehensive Stock Analysis
This article provides a comprehensive stock analysis of Halozyme Therapeutics Inc (HALO), highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis notes significant institutional ownership and a "Buy" rating from analysts with an average target price of $89.25. The stock score is generated from 34 indicators across financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment.
Halozyme Therapeutics Inc (HALO) Financial Health: Profitability & Balance Sheet Analysis
Halozyme Therapeutics Inc (HALO) currently holds a financial score of 8.39, placing it 51st out of 155 companies in the Pharmaceuticals industry. While its overall financial status is deemed weak, its operating efficiency is high. The company recently reported a 42.23% year-over-year increase in quarterly revenue and a 27.06% increase in net profit.
4% Undervalued? Halozyme Therapeutics (HALO) Nears Earnings At A Record High
Halozyme Therapeutics (HALO) has reached a record high ahead of its earnings release, with a 3-year shareholder return of 94.35%. While its valuation is considered 4.2% undervalued by some at $86.89 due to expanding partnerships and new product launches, its P/E ratio of 28.3x is higher than the biotech industry average, suggesting less room for error. Investors are advised to review the full data set, considering both potential rewards and warning signs, including concentrated royalties and ongoing patent challenges.
